Global Amyotrophic Lateral Sclerosis (ALS) Market Growth 2025-2031
The global Amyotrophic Lateral Sclerosis (ALS) market size is predicted to grow from US$ 333 million in 2025 to US$ 391 million in 2031; it is expected to grow at a CAGR of 2.7% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
The amyotrophic lateral sclerosis (ALS) therapeutics market is driven by the increasing prevalence of ALS and the growing demand for effective treatments to slow disease progression and improve patient outcomes. As the understanding of ALS pathophysiology improves, researchers and pharmaceutical companies are actively exploring novel therapeutic approaches, including gene therapies and immune-modulating agents. The approval of new ALS drugs and the development of combination therapies further propel market growth. However, challenges include the complexity of ALS as a multi-factorial disease, the difficulty in diagnosing ALS at an early stage, and the high cost of drug development and clinical trials. Addressing these challenges through collaborative research, improved diagnostic tools, and accessible treatment options will be crucial for the sustained growth of the ALS therapeutics market.
LP Information, Inc. (LPI) ' newest research report, the “Amyotrophic Lateral Sclerosis (ALS) Industry Forecast” looks at past sales and reviews total world Amyotrophic Lateral Sclerosis (ALS) sales in 2024, providing a comprehensive analysis by region and market sector of projected Amyotrophic Lateral Sclerosis (ALS) sales for 2025 through 2031. With Amyotrophic Lateral Sclerosis (ALS) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Amyotrophic Lateral Sclerosis (ALS) industry.
This Insight Report provides a comprehensive analysis of the global Amyotrophic Lateral Sclerosis (ALS) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Amyotrophic Lateral Sclerosis (ALS) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Amyotrophic Lateral Sclerosis (ALS) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Amyotrophic Lateral Sclerosis (ALS) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Amyotrophic Lateral Sclerosis (ALS).
This report presents a comprehensive overview, market shares, and growth opportunities of Amyotrophic Lateral Sclerosis (ALS) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Amyotrophic Lateral Sclerosis (ALS) market?
What factors are driving Amyotrophic Lateral Sclerosis (ALS) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Amyotrophic Lateral Sclerosis (ALS) market opportunities vary by end market size?
How does Amyotrophic Lateral Sclerosis (ALS) break out by Type, by Application?
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
The amyotrophic lateral sclerosis (ALS) therapeutics market is driven by the increasing prevalence of ALS and the growing demand for effective treatments to slow disease progression and improve patient outcomes. As the understanding of ALS pathophysiology improves, researchers and pharmaceutical companies are actively exploring novel therapeutic approaches, including gene therapies and immune-modulating agents. The approval of new ALS drugs and the development of combination therapies further propel market growth. However, challenges include the complexity of ALS as a multi-factorial disease, the difficulty in diagnosing ALS at an early stage, and the high cost of drug development and clinical trials. Addressing these challenges through collaborative research, improved diagnostic tools, and accessible treatment options will be crucial for the sustained growth of the ALS therapeutics market.
LP Information, Inc. (LPI) ' newest research report, the “Amyotrophic Lateral Sclerosis (ALS) Industry Forecast” looks at past sales and reviews total world Amyotrophic Lateral Sclerosis (ALS) sales in 2024, providing a comprehensive analysis by region and market sector of projected Amyotrophic Lateral Sclerosis (ALS) sales for 2025 through 2031. With Amyotrophic Lateral Sclerosis (ALS) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Amyotrophic Lateral Sclerosis (ALS) industry.
This Insight Report provides a comprehensive analysis of the global Amyotrophic Lateral Sclerosis (ALS) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Amyotrophic Lateral Sclerosis (ALS) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Amyotrophic Lateral Sclerosis (ALS) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Amyotrophic Lateral Sclerosis (ALS) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Amyotrophic Lateral Sclerosis (ALS).
This report presents a comprehensive overview, market shares, and growth opportunities of Amyotrophic Lateral Sclerosis (ALS) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Riluzole
- Edaravone (Radicava)
- Other
- Hospital
- Drugs Store
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Mitsubishi Tanabe Pharma
- Sanofi
- Mylan Pharma
- Apotex
- Glemark Generics
- Covis Pharma
- Sun Pharma
- Lunan Pharma
What is the 10-year outlook for the global Amyotrophic Lateral Sclerosis (ALS) market?
What factors are driving Amyotrophic Lateral Sclerosis (ALS) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Amyotrophic Lateral Sclerosis (ALS) market opportunities vary by end market size?
How does Amyotrophic Lateral Sclerosis (ALS) break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Amyotrophic Lateral Sclerosis (ALS) by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Amyotrophic Lateral Sclerosis (ALS) by Country/Region, 2020, 2024 & 2031
2.2 Amyotrophic Lateral Sclerosis (ALS) Segment by Type
2.2.1 Riluzole
2.2.2 Edaravone (Radicava)
2.2.3 Other
2.3 Amyotrophic Lateral Sclerosis (ALS) Sales by Type
2.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2020-2025)
2.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue and Market Share by Type (2020-2025)
2.3.3 Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Type (2020-2025)
2.4 Amyotrophic Lateral Sclerosis (ALS) Segment by Application
2.4.1 Hospital
2.4.2 Drugs Store
2.4.3 Other
2.5 Amyotrophic Lateral Sclerosis (ALS) Sales by Application
2.5.1 Global Amyotrophic Lateral Sclerosis (ALS) Sale Market Share by Application (2020-2025)
2.5.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue and Market Share by Application (2020-2025)
2.5.3 Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Amyotrophic Lateral Sclerosis (ALS) Breakdown Data by Company
3.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Annual Sales by Company (2020-2025)
3.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Company (2020-2025)
3.2 Global Amyotrophic Lateral Sclerosis (ALS) Annual Revenue by Company (2020-2025)
3.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Company (2020-2025)
3.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Company (2020-2025)
3.3 Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Company
3.4 Key Manufacturers Amyotrophic Lateral Sclerosis (ALS) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Amyotrophic Lateral Sclerosis (ALS) Product Location Distribution
3.4.2 Players Amyotrophic Lateral Sclerosis (ALS) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) BY GEOGRAPHIC REGION
4.1 World Historic Amyotrophic Lateral Sclerosis (ALS) Market Size by Geographic Region (2020-2025)
4.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Amyotrophic Lateral Sclerosis (ALS) Market Size by Country/Region (2020-2025)
4.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Annual Sales by Country/Region (2020-2025)
4.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Annual Revenue by Country/Region (2020-2025)
4.3 Americas Amyotrophic Lateral Sclerosis (ALS) Sales Growth
4.4 APAC Amyotrophic Lateral Sclerosis (ALS) Sales Growth
4.5 Europe Amyotrophic Lateral Sclerosis (ALS) Sales Growth
4.6 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Growth
5 AMERICAS
5.1 Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Country
5.1.1 Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2020-2025)
5.1.2 Americas Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2020-2025)
5.2 Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2020-2025)
5.3 Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Region
6.1.1 APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2020-2025)
6.1.2 APAC Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2020-2025)
6.2 APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2020-2025)
6.3 APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Amyotrophic Lateral Sclerosis (ALS) by Country
7.1.1 Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2020-2025)
7.1.2 Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2020-2025)
7.2 Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2020-2025)
7.3 Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) by Country
8.1.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2020-2025)
8.1.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2020-2025)
8.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2020-2025)
8.3 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Amyotrophic Lateral Sclerosis (ALS)
10.3 Manufacturing Process Analysis of Amyotrophic Lateral Sclerosis (ALS)
10.4 Industry Chain Structure of Amyotrophic Lateral Sclerosis (ALS)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Amyotrophic Lateral Sclerosis (ALS) Distributors
11.3 Amyotrophic Lateral Sclerosis (ALS) Customer
12 WORLD FORECAST REVIEW FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) BY GEOGRAPHIC REGION
12.1 Global Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Region
12.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Forecast by Region (2026-2031)
12.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Amyotrophic Lateral Sclerosis (ALS) Forecast by Type (2026-2031)
12.7 Global Amyotrophic Lateral Sclerosis (ALS) Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Mitsubishi Tanabe Pharma
13.1.1 Mitsubishi Tanabe Pharma Company Information
13.1.2 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Mitsubishi Tanabe Pharma Main Business Overview
13.1.5 Mitsubishi Tanabe Pharma Latest Developments
13.2 Sanofi
13.2.1 Sanofi Company Information
13.2.2 Sanofi Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Sanofi Main Business Overview
13.2.5 Sanofi Latest Developments
13.3 Mylan Pharma
13.3.1 Mylan Pharma Company Information
13.3.2 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Mylan Pharma Main Business Overview
13.3.5 Mylan Pharma Latest Developments
13.4 Apotex
13.4.1 Apotex Company Information
13.4.2 Apotex Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Apotex Main Business Overview
13.4.5 Apotex Latest Developments
13.5 Glemark Generics
13.5.1 Glemark Generics Company Information
13.5.2 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Glemark Generics Main Business Overview
13.5.5 Glemark Generics Latest Developments
13.6 Covis Pharma
13.6.1 Covis Pharma Company Information
13.6.2 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Covis Pharma Main Business Overview
13.6.5 Covis Pharma Latest Developments
13.7 Sun Pharma
13.7.1 Sun Pharma Company Information
13.7.2 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Sun Pharma Main Business Overview
13.7.5 Sun Pharma Latest Developments
13.8 Lunan Pharma
13.8.1 Lunan Pharma Company Information
13.8.2 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Lunan Pharma Main Business Overview
13.8.5 Lunan Pharma Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Amyotrophic Lateral Sclerosis (ALS) by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Amyotrophic Lateral Sclerosis (ALS) by Country/Region, 2020, 2024 & 2031
2.2 Amyotrophic Lateral Sclerosis (ALS) Segment by Type
2.2.1 Riluzole
2.2.2 Edaravone (Radicava)
2.2.3 Other
2.3 Amyotrophic Lateral Sclerosis (ALS) Sales by Type
2.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2020-2025)
2.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue and Market Share by Type (2020-2025)
2.3.3 Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Type (2020-2025)
2.4 Amyotrophic Lateral Sclerosis (ALS) Segment by Application
2.4.1 Hospital
2.4.2 Drugs Store
2.4.3 Other
2.5 Amyotrophic Lateral Sclerosis (ALS) Sales by Application
2.5.1 Global Amyotrophic Lateral Sclerosis (ALS) Sale Market Share by Application (2020-2025)
2.5.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue and Market Share by Application (2020-2025)
2.5.3 Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Amyotrophic Lateral Sclerosis (ALS) Breakdown Data by Company
3.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Annual Sales by Company (2020-2025)
3.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Company (2020-2025)
3.2 Global Amyotrophic Lateral Sclerosis (ALS) Annual Revenue by Company (2020-2025)
3.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Company (2020-2025)
3.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Company (2020-2025)
3.3 Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Company
3.4 Key Manufacturers Amyotrophic Lateral Sclerosis (ALS) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Amyotrophic Lateral Sclerosis (ALS) Product Location Distribution
3.4.2 Players Amyotrophic Lateral Sclerosis (ALS) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) BY GEOGRAPHIC REGION
4.1 World Historic Amyotrophic Lateral Sclerosis (ALS) Market Size by Geographic Region (2020-2025)
4.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Amyotrophic Lateral Sclerosis (ALS) Market Size by Country/Region (2020-2025)
4.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Annual Sales by Country/Region (2020-2025)
4.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Annual Revenue by Country/Region (2020-2025)
4.3 Americas Amyotrophic Lateral Sclerosis (ALS) Sales Growth
4.4 APAC Amyotrophic Lateral Sclerosis (ALS) Sales Growth
4.5 Europe Amyotrophic Lateral Sclerosis (ALS) Sales Growth
4.6 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Growth
5 AMERICAS
5.1 Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Country
5.1.1 Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2020-2025)
5.1.2 Americas Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2020-2025)
5.2 Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2020-2025)
5.3 Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Region
6.1.1 APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2020-2025)
6.1.2 APAC Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2020-2025)
6.2 APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2020-2025)
6.3 APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Amyotrophic Lateral Sclerosis (ALS) by Country
7.1.1 Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2020-2025)
7.1.2 Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2020-2025)
7.2 Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2020-2025)
7.3 Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) by Country
8.1.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2020-2025)
8.1.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2020-2025)
8.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2020-2025)
8.3 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Amyotrophic Lateral Sclerosis (ALS)
10.3 Manufacturing Process Analysis of Amyotrophic Lateral Sclerosis (ALS)
10.4 Industry Chain Structure of Amyotrophic Lateral Sclerosis (ALS)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Amyotrophic Lateral Sclerosis (ALS) Distributors
11.3 Amyotrophic Lateral Sclerosis (ALS) Customer
12 WORLD FORECAST REVIEW FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) BY GEOGRAPHIC REGION
12.1 Global Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Region
12.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Forecast by Region (2026-2031)
12.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Amyotrophic Lateral Sclerosis (ALS) Forecast by Type (2026-2031)
12.7 Global Amyotrophic Lateral Sclerosis (ALS) Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Mitsubishi Tanabe Pharma
13.1.1 Mitsubishi Tanabe Pharma Company Information
13.1.2 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Mitsubishi Tanabe Pharma Main Business Overview
13.1.5 Mitsubishi Tanabe Pharma Latest Developments
13.2 Sanofi
13.2.1 Sanofi Company Information
13.2.2 Sanofi Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Sanofi Main Business Overview
13.2.5 Sanofi Latest Developments
13.3 Mylan Pharma
13.3.1 Mylan Pharma Company Information
13.3.2 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Mylan Pharma Main Business Overview
13.3.5 Mylan Pharma Latest Developments
13.4 Apotex
13.4.1 Apotex Company Information
13.4.2 Apotex Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Apotex Main Business Overview
13.4.5 Apotex Latest Developments
13.5 Glemark Generics
13.5.1 Glemark Generics Company Information
13.5.2 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Glemark Generics Main Business Overview
13.5.5 Glemark Generics Latest Developments
13.6 Covis Pharma
13.6.1 Covis Pharma Company Information
13.6.2 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Covis Pharma Main Business Overview
13.6.5 Covis Pharma Latest Developments
13.7 Sun Pharma
13.7.1 Sun Pharma Company Information
13.7.2 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Sun Pharma Main Business Overview
13.7.5 Sun Pharma Latest Developments
13.8 Lunan Pharma
13.8.1 Lunan Pharma Company Information
13.8.2 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
13.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Lunan Pharma Main Business Overview
13.8.5 Lunan Pharma Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Amyotrophic Lateral Sclerosis (ALS) Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Amyotrophic Lateral Sclerosis (ALS) Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Riluzole
Table 4. Major Players of Edaravone (Radicava)
Table 5. Major Players of Other
Table 6. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2020-2025) & (K Unit)
Table 7. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2020-2025)
Table 8. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2020-2025) & ($ million)
Table 9. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2020-2025)
Table 10. Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Type (2020-2025) & (USD/Unit)
Table 11. Global Amyotrophic Lateral Sclerosis (ALS) Sale by Application (2020-2025) & (K Unit)
Table 12. Global Amyotrophic Lateral Sclerosis (ALS) Sale Market Share by Application (2020-2025)
Table 13. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2020-2025) & ($ million)
Table 14. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2020-2025)
Table 15. Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Application (2020-2025) & (USD/Unit)
Table 16. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Company (2020-2025) & (K Unit)
Table 17. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Company (2020-2025)
Table 18. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Company (2020-2025)
Table 20. Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Company (2020-2025) & (USD/Unit)
Table 21. Key Manufacturers Amyotrophic Lateral Sclerosis (ALS) Producing Area Distribution and Sales Area
Table 22. Players Amyotrophic Lateral Sclerosis (ALS) Products Offered
Table 23. Amyotrophic Lateral Sclerosis (ALS) Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Geographic Region (2020-2025) & (K Unit)
Table 27. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share Geographic Region (2020-2025)
Table 28. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Country/Region (2020-2025) & (K Unit)
Table 31. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country/Region (2020-2025)
Table 32. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2020-2025) & (K Unit)
Table 35. Americas Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2020-2025)
Table 36. Americas Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2020-2025) & (K Unit)
Table 38. Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2020-2025) & (K Unit)
Table 39. APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2020-2025) & (K Unit)
Table 40. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Region (2020-2025)
Table 41. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2020-2025) & (K Unit)
Table 43. APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2020-2025) & (K Unit)
Table 44. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2020-2025) & (K Unit)
Table 45. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2020-2025) & (K Unit)
Table 47. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2020-2025) & (K Unit)
Table 48. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2020-2025) & (K Unit)
Table 49. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2020-2025) & (K Unit)
Table 51. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2020-2025) & (K Unit)
Table 52. Key Market Drivers & Growth Opportunities of Amyotrophic Lateral Sclerosis (ALS)
Table 53. Key Market Challenges & Risks of Amyotrophic Lateral Sclerosis (ALS)
Table 54. Key Industry Trends of Amyotrophic Lateral Sclerosis (ALS)
Table 55. Amyotrophic Lateral Sclerosis (ALS) Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Amyotrophic Lateral Sclerosis (ALS) Distributors List
Table 58. Amyotrophic Lateral Sclerosis (ALS) Customer List
Table 59. Global Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Region (2026-2031) & (K Unit)
Table 60. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Forecast by Region (2026-2031) & ($ millions)
Table 61. Americas Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Country (2026-2031) & (K Unit)
Table 62. Americas Amyotrophic Lateral Sclerosis (ALS) Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 63. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Region (2026-2031) & (K Unit)
Table 64. APAC Amyotrophic Lateral Sclerosis (ALS) Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 65. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Country (2026-2031) & (K Unit)
Table 66. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue Forecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Country (2026-2031) & (K Unit)
Table 68. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Global Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Type (2026-2031) & (K Unit)
Table 70. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Forecast by Type (2026-2031) & ($ millions)
Table 71. Global Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Application (2026-2031) & (K Unit)
Table 72. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Forecast by Application (2026-2031) & ($ millions)
Table 73. Mitsubishi Tanabe Pharma Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 74. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 75. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 76. Mitsubishi Tanabe Pharma Main Business
Table 77. Mitsubishi Tanabe Pharma Latest Developments
Table 78. Sanofi Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 79. Sanofi Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 80. Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 81. Sanofi Main Business
Table 82. Sanofi Latest Developments
Table 83. Mylan Pharma Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 84. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 85. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 86. Mylan Pharma Main Business
Table 87. Mylan Pharma Latest Developments
Table 88. Apotex Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 89. Apotex Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 90. Apotex Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 91. Apotex Main Business
Table 92. Apotex Latest Developments
Table 93. Glemark Generics Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 94. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 95. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 96. Glemark Generics Main Business
Table 97. Glemark Generics Latest Developments
Table 98. Covis Pharma Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 99. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 100. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 101. Covis Pharma Main Business
Table 102. Covis Pharma Latest Developments
Table 103. Sun Pharma Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 104. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 105. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 106. Sun Pharma Main Business
Table 107. Sun Pharma Latest Developments
Table 108. Lunan Pharma Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 109. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 110. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 111. Lunan Pharma Main Business
Table 112. Lunan Pharma Latest Developments
Table 1. Amyotrophic Lateral Sclerosis (ALS) Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Amyotrophic Lateral Sclerosis (ALS) Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Riluzole
Table 4. Major Players of Edaravone (Radicava)
Table 5. Major Players of Other
Table 6. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2020-2025) & (K Unit)
Table 7. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2020-2025)
Table 8. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2020-2025) & ($ million)
Table 9. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2020-2025)
Table 10. Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Type (2020-2025) & (USD/Unit)
Table 11. Global Amyotrophic Lateral Sclerosis (ALS) Sale by Application (2020-2025) & (K Unit)
Table 12. Global Amyotrophic Lateral Sclerosis (ALS) Sale Market Share by Application (2020-2025)
Table 13. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2020-2025) & ($ million)
Table 14. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2020-2025)
Table 15. Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Application (2020-2025) & (USD/Unit)
Table 16. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Company (2020-2025) & (K Unit)
Table 17. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Company (2020-2025)
Table 18. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Company (2020-2025)
Table 20. Global Amyotrophic Lateral Sclerosis (ALS) Sale Price by Company (2020-2025) & (USD/Unit)
Table 21. Key Manufacturers Amyotrophic Lateral Sclerosis (ALS) Producing Area Distribution and Sales Area
Table 22. Players Amyotrophic Lateral Sclerosis (ALS) Products Offered
Table 23. Amyotrophic Lateral Sclerosis (ALS) Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Geographic Region (2020-2025) & (K Unit)
Table 27. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share Geographic Region (2020-2025)
Table 28. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Country/Region (2020-2025) & (K Unit)
Table 31. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country/Region (2020-2025)
Table 32. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2020-2025) & (K Unit)
Table 35. Americas Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2020-2025)
Table 36. Americas Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2020-2025) & (K Unit)
Table 38. Americas Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2020-2025) & (K Unit)
Table 39. APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2020-2025) & (K Unit)
Table 40. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Region (2020-2025)
Table 41. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2020-2025) & (K Unit)
Table 43. APAC Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2020-2025) & (K Unit)
Table 44. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2020-2025) & (K Unit)
Table 45. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2020-2025) & (K Unit)
Table 47. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2020-2025) & (K Unit)
Table 48. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2020-2025) & (K Unit)
Table 49. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2020-2025) & (K Unit)
Table 51. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2020-2025) & (K Unit)
Table 52. Key Market Drivers & Growth Opportunities of Amyotrophic Lateral Sclerosis (ALS)
Table 53. Key Market Challenges & Risks of Amyotrophic Lateral Sclerosis (ALS)
Table 54. Key Industry Trends of Amyotrophic Lateral Sclerosis (ALS)
Table 55. Amyotrophic Lateral Sclerosis (ALS) Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Amyotrophic Lateral Sclerosis (ALS) Distributors List
Table 58. Amyotrophic Lateral Sclerosis (ALS) Customer List
Table 59. Global Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Region (2026-2031) & (K Unit)
Table 60. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Forecast by Region (2026-2031) & ($ millions)
Table 61. Americas Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Country (2026-2031) & (K Unit)
Table 62. Americas Amyotrophic Lateral Sclerosis (ALS) Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 63. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Region (2026-2031) & (K Unit)
Table 64. APAC Amyotrophic Lateral Sclerosis (ALS) Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 65. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Country (2026-2031) & (K Unit)
Table 66. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue Forecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Country (2026-2031) & (K Unit)
Table 68. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Global Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Type (2026-2031) & (K Unit)
Table 70. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Forecast by Type (2026-2031) & ($ millions)
Table 71. Global Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Application (2026-2031) & (K Unit)
Table 72. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Forecast by Application (2026-2031) & ($ millions)
Table 73. Mitsubishi Tanabe Pharma Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 74. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 75. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 76. Mitsubishi Tanabe Pharma Main Business
Table 77. Mitsubishi Tanabe Pharma Latest Developments
Table 78. Sanofi Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 79. Sanofi Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 80. Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 81. Sanofi Main Business
Table 82. Sanofi Latest Developments
Table 83. Mylan Pharma Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 84. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 85. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 86. Mylan Pharma Main Business
Table 87. Mylan Pharma Latest Developments
Table 88. Apotex Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 89. Apotex Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 90. Apotex Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 91. Apotex Main Business
Table 92. Apotex Latest Developments
Table 93. Glemark Generics Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 94. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 95. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 96. Glemark Generics Main Business
Table 97. Glemark Generics Latest Developments
Table 98. Covis Pharma Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 99. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 100. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 101. Covis Pharma Main Business
Table 102. Covis Pharma Latest Developments
Table 103. Sun Pharma Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 104. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 105. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 106. Sun Pharma Main Business
Table 107. Sun Pharma Latest Developments
Table 108. Lunan Pharma Basic Information, Amyotrophic Lateral Sclerosis (ALS) Manufacturing Base, Sales Area and Its Competitors
Table 109. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolios and Specifications
Table 110. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 111. Lunan Pharma Main Business
Table 112. Lunan Pharma Latest Developments
LIST OF FIGURES
Figure 1. Picture of Amyotrophic Lateral Sclerosis (ALS)
Figure 2. Amyotrophic Lateral Sclerosis (ALS) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Amyotrophic Lateral Sclerosis (ALS) Sales Growth Rate 2020-2031 (K Unit)
Figure 7. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Amyotrophic Lateral Sclerosis (ALS) Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country/Region (2024)
Figure 10. Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Riluzole
Figure 12. Product Picture of Edaravone (Radicava)
Figure 13. Product Picture of Other
Figure 14. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type in 2025
Figure 15. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2020-2025)
Figure 16. Amyotrophic Lateral Sclerosis (ALS) Consumed in Hospital
Figure 17. Global Amyotrophic Lateral Sclerosis (ALS) Market: Hospital (2020-2025) & (K Unit)
Figure 18. Amyotrophic Lateral Sclerosis (ALS) Consumed in Drugs Store
Figure 19. Global Amyotrophic Lateral Sclerosis (ALS) Market: Drugs Store (2020-2025) & (K Unit)
Figure 20. Amyotrophic Lateral Sclerosis (ALS) Consumed in Other
Figure 21. Global Amyotrophic Lateral Sclerosis (ALS) Market: Other (2020-2025) & (K Unit)
Figure 22. Global Amyotrophic Lateral Sclerosis (ALS) Sale Market Share by Application (2024)
Figure 23. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application in 2025
Figure 24. Amyotrophic Lateral Sclerosis (ALS) Sales by Company in 2025 (K Unit)
Figure 25. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Company in 2025
Figure 26. Amyotrophic Lateral Sclerosis (ALS) Revenue by Company in 2025 ($ millions)
Figure 27. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Company in 2025
Figure 28. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Geographic Region (2020-2025)
Figure 29. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Geographic Region in 2025
Figure 30. Americas Amyotrophic Lateral Sclerosis (ALS) Sales 2020-2025 (K Unit)
Figure 31. Americas Amyotrophic Lateral Sclerosis (ALS) Revenue 2020-2025 ($ millions)
Figure 32. APAC Amyotrophic Lateral Sclerosis (ALS) Sales 2020-2025 (K Unit)
Figure 33. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue 2020-2025 ($ millions)
Figure 34. Europe Amyotrophic Lateral Sclerosis (ALS) Sales 2020-2025 (K Unit)
Figure 35. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue 2020-2025 ($ millions)
Figure 36. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales 2020-2025 (K Unit)
Figure 37. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Revenue 2020-2025 ($ millions)
Figure 38. Americas Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country in 2025
Figure 39. Americas Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country (2020-2025)
Figure 40. Americas Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2020-2025)
Figure 41. Americas Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2020-2025)
Figure 42. United States Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 43. Canada Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 44. Mexico Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 45. Brazil Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 46. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Region in 2025
Figure 47. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Region (2020-2025)
Figure 48. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2020-2025)
Figure 49. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2020-2025)
Figure 50. China Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 51. Japan Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 52. South Korea Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 53. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 54. India Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 55. Australia Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 56. China Taiwan Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 57. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country in 2025
Figure 58. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country (2020-2025)
Figure 59. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2020-2025)
Figure 60. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2020-2025)
Figure 61. Germany Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 62. France Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 63. UK Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 64. Italy Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 65. Russia Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 66. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2020-2025)
Figure 67. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2020-2025)
Figure 68. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2020-2025)
Figure 69. Egypt Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 70. South Africa Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 71. Israel Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 72. Turkey Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 73. GCC Countries Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Amyotrophic Lateral Sclerosis (ALS) in 2025
Figure 75. Manufacturing Process Analysis of Amyotrophic Lateral Sclerosis (ALS)
Figure 76. Industry Chain Structure of Amyotrophic Lateral Sclerosis (ALS)
Figure 77. Channels of Distribution
Figure 78. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Forecast by Region (2026-2031)
Figure 79. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share Forecast by Region (2026-2031)
Figure 80. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share Forecast by Type (2026-2031)
Figure 81. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share Forecast by Type (2026-2031)
Figure 82. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share Forecast by Application (2026-2031)
Figure 83. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share Forecast by Application (2026-2031)
Figure 1. Picture of Amyotrophic Lateral Sclerosis (ALS)
Figure 2. Amyotrophic Lateral Sclerosis (ALS) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Amyotrophic Lateral Sclerosis (ALS) Sales Growth Rate 2020-2031 (K Unit)
Figure 7. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Amyotrophic Lateral Sclerosis (ALS) Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country/Region (2024)
Figure 10. Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Riluzole
Figure 12. Product Picture of Edaravone (Radicava)
Figure 13. Product Picture of Other
Figure 14. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type in 2025
Figure 15. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2020-2025)
Figure 16. Amyotrophic Lateral Sclerosis (ALS) Consumed in Hospital
Figure 17. Global Amyotrophic Lateral Sclerosis (ALS) Market: Hospital (2020-2025) & (K Unit)
Figure 18. Amyotrophic Lateral Sclerosis (ALS) Consumed in Drugs Store
Figure 19. Global Amyotrophic Lateral Sclerosis (ALS) Market: Drugs Store (2020-2025) & (K Unit)
Figure 20. Amyotrophic Lateral Sclerosis (ALS) Consumed in Other
Figure 21. Global Amyotrophic Lateral Sclerosis (ALS) Market: Other (2020-2025) & (K Unit)
Figure 22. Global Amyotrophic Lateral Sclerosis (ALS) Sale Market Share by Application (2024)
Figure 23. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application in 2025
Figure 24. Amyotrophic Lateral Sclerosis (ALS) Sales by Company in 2025 (K Unit)
Figure 25. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Company in 2025
Figure 26. Amyotrophic Lateral Sclerosis (ALS) Revenue by Company in 2025 ($ millions)
Figure 27. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Company in 2025
Figure 28. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Geographic Region (2020-2025)
Figure 29. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Geographic Region in 2025
Figure 30. Americas Amyotrophic Lateral Sclerosis (ALS) Sales 2020-2025 (K Unit)
Figure 31. Americas Amyotrophic Lateral Sclerosis (ALS) Revenue 2020-2025 ($ millions)
Figure 32. APAC Amyotrophic Lateral Sclerosis (ALS) Sales 2020-2025 (K Unit)
Figure 33. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue 2020-2025 ($ millions)
Figure 34. Europe Amyotrophic Lateral Sclerosis (ALS) Sales 2020-2025 (K Unit)
Figure 35. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue 2020-2025 ($ millions)
Figure 36. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales 2020-2025 (K Unit)
Figure 37. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Revenue 2020-2025 ($ millions)
Figure 38. Americas Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country in 2025
Figure 39. Americas Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country (2020-2025)
Figure 40. Americas Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2020-2025)
Figure 41. Americas Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2020-2025)
Figure 42. United States Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 43. Canada Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 44. Mexico Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 45. Brazil Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 46. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Region in 2025
Figure 47. APAC Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Region (2020-2025)
Figure 48. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2020-2025)
Figure 49. APAC Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2020-2025)
Figure 50. China Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 51. Japan Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 52. South Korea Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 53. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 54. India Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 55. Australia Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 56. China Taiwan Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 57. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country in 2025
Figure 58. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country (2020-2025)
Figure 59. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2020-2025)
Figure 60. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2020-2025)
Figure 61. Germany Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 62. France Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 63. UK Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 64. Italy Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 65. Russia Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 66. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2020-2025)
Figure 67. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2020-2025)
Figure 68. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2020-2025)
Figure 69. Egypt Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 70. South Africa Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 71. Israel Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 72. Turkey Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 73. GCC Countries Amyotrophic Lateral Sclerosis (ALS) Revenue Growth 2020-2025 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Amyotrophic Lateral Sclerosis (ALS) in 2025
Figure 75. Manufacturing Process Analysis of Amyotrophic Lateral Sclerosis (ALS)
Figure 76. Industry Chain Structure of Amyotrophic Lateral Sclerosis (ALS)
Figure 77. Channels of Distribution
Figure 78. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Forecast by Region (2026-2031)
Figure 79. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share Forecast by Region (2026-2031)
Figure 80. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share Forecast by Type (2026-2031)
Figure 81. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share Forecast by Type (2026-2031)
Figure 82. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share Forecast by Application (2026-2031)
Figure 83. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share Forecast by Application (2026-2031)
More Publications
Global Intubation Scopes Market Growth 2023-2029
US$ 3,660.00
March 2023
101 pages
Global Integrated Operating Room Systems Market Growth (Status and Outlook) 2024-2030
US$ 3,660.00
August 2024
110 pages
Global Warfarin Sensitivity Testing Market Growth (Status and Outlook) 2025-2031
US$ 3,660.00
September 2025
97 pages
Global Venous Procedure Devices Market Growth 2023-2029
US$ 3,660.00
March 2023
111 pages
